especially in light of the published middling numbers for Lympro going back 15 years.
The ability of GC to move the stock based on his pronouncements that he had great data should have died after his first attempt in Jan 2013. Each time he said that he could not reveal the data until the so called event. He repeated the same thing successfully in 2014. both times the stock popped, in association with promotions in the penny stock world. Both times the pps bubble popped amid data that was anything but positive.
Perhaps in 2015 the market will wait for the data to actually be good instead of reacting to a study that had four subjects in the first place, and a study that was not positive, and hid its data in the second place.
Lympro can have some utility in screening for AD in research, but it is very limited. Now they are talking about combining it with the Georgetown test, which means that Lympro, in the opinion of AMBS cannot stand alone.
That said, the combination of Lympro AND the Georgetown test may well be an excellent test. That has not been studied yet.
I almost forgot the conference on concussions held at the rented UN last year. They offered a so called study that had only 10 subjects only to be rebuked by one of the panelists who called for robust science. The company had promised data but could only deliver 10 patients. that is absurd.
This company has a history of horrible credibility. That is why the pps is five cents now, and they had to sell stock at five cents about a month ago in order to continue to fund the company.
When you sell stock at a particular level, that values the company AT that level and not higher. It also presents a serious drag on future appreciation of the stock.
News 
Market Data 
Discover 
